LB1410 is a PD-1/TIM-3 bispecific antibody product independently developed by L&L Bio with proprietary intellectual property rights. It retains the antitumor activity of pembrolizumab (Keytruda) and adds TIM-3 pathway blockade, thereby simultaneously blocking the PD-1/PD-L1 and TIM-3/ligand signaling pathways and exerting enhanced synergistic effects on regulation of the immune microenvironment. In addition to restoring T cell–mediated tumor-killing activity,  LB1410 can bridge dendritic cells (DCs) and T cells to enhance antitumor immune responses and is also capable of restoring natural killer (NK) cell immune activity.

LB1410 has been approved for clinical trials in both China and the United States. Among bispecific antibody candidates targeting the same pathways, LB1410 is at the forefront in terms of clinical development progress and is the first globally to advance into clinical studies among patients with immunotherapy-resistant tumors. To date, 94 patients have been enrolled in the Phase I clinical study, with data demonstrating a excellent safety profile. Moreover, LB1410 has shown promising efficacy across multiple solid tumors that are unresponsive or resistant to anti-PD-1/PD-L1 antibody therapies, including cervical cancer, hepatocellular carcinoma, renal cell carcinoma, lung cancer, esophageal cancer, colorectal cancer, urothelial carcinoma, skin cancers, and lymphoma. Notably, an ORR of 38.5% and a DCR of 69.2% have been observed among patients with immunotherapy-resistant cervical cancer. Phase II/III clinical trials of LB1410 as monotherapy and in combination with lenvatinib are currently being conducted at around 20 clinical centers in China.